|1||NCT01445379||Completed||Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer||
||29||All||3 Years to 21 Years (Child, Adult)||NCT01445379||080007
|October 1, 2007||April 18, 2014||November 13, 2015||October 3, 2011||October 6, 2017||
|2||NCT01440413||Active, not recruiting||Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer||
||40||Female||18 Years and older (Adult, Senior)||NCT01440413||BREAST IMMUN
|BREAST IMMUN||December 2011||December 2018||December 2018||September 26, 2011||February 1, 2017||
† Study has passed its completion date and status has not been verified in more than two years.